Inhibrx Biosciences, Inc.
- Last sale
- Nov 12, 2026 · -3.39%
- Market cap
- $1.30B
- 14.77M shares
- Filings
- 162
Q3 2026+550.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−18.6% FY25 yoy
- $1.30B
- —
- 996.2×
- —
- -10.02%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,300,000 | reported | |
| FY 2024 | 2024-12-31 | $200,000 | reported | |
| FY 2023 | 2023-12-31 | $1,800,000 | reported |
Segments
Products
LineFY2025ShareChange
License fee revenue$1.30M100%+550.0%
License fee revenue$1.30M100%+550.0%
Total$1.30M
Biological products, except diagnostic substances
Inhibrx Biosciences, Inc. is the 78th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
ALGSAligos Therapeutics, Inc.$2.2M39.5%1,106.7%$12.6MHUMAHumacyte, Inc.$2.0M—2,003.6%$165.5MOTLKOutlook Therapeutics, Inc.$1.4M—4,416.2%$107.1MSCNIScinai Immunotherapeutics Ltd.$1.3M99.2%633.6%$1.6M
INBXInhibrx Biosciences, Inc. (this company)$1.3M550.0%10,773.5%$1.3B
PLURPluri Inc.$1.0M24.0%2,344.6%$17.3MPROKProkidney Corp.$893.0K1,075.0%7,725.2%$347.7MIMAImageneBio, Inc.$800.0K77.1%5,668.6%$45.0MCRDFCardiff Oncology, Inc.$593.0K13.2%7,732.0%$56.8MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Inhibrx Biosciences, Inc. · CIK 2007919 · Engraved from SEC EDGAR